A qualitative evaluation of general practitioners' perceptions regarding access to medicines in New Zealand

BMJ Open

Volumn 2, Issue 2, 2012, Pages

  Babar, Zaheer Ud Din ^a   Grover, Piyush ^b   Butler, Rachael ^c   Bye, Lynne ^a   Sheridan, Janie ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ADULT; ARTICLE; FEMALE; FUNDING; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HUMAN; MALE; NEW ZEALAND; PERCEPTION; QUALITATIVE ANALYSIS;

EID: 84860153622     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000518     Document Type: Article

References (42)

1. Associate Minister of Healthd Ministry of Health. Medicines New Zealand: Contributing to Good Health Outcomes For All New Zealanders. Wellington: Ministry of health, 2007.
2. Morgan S, Hanley G, McMahon M, et al. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthcare Policy 2007;3:121-40.
3. PHARMAC. Pharmac Information Sheet: The Introduction to PHARMAC. Wellington: New Zealand, 2010.
4. Pharmaceutical Management Agency of New Zealand. The Truth About Generic Medicines. Pharmac Info Sheet. Wellington: PHARMAC, 2010.
5. Pharmaceutical Management Agency of New Zealand. Making Funding Decisions: Pharmac Info Sheet. Wellington: PHARMAC, 2008.
6. Pharmaceutical Management Agency. Pharmaceutical Schedule. Wellington: PHARMAC, 2011.
7. Morgan S, Boothe K. Prescription drug subsidies in Australia and New Zealand. Australian Prescriber 2010;33:2-4.
8. Glover J, Hetzel D, Tennant S. Australia and New Zealand, Health Systems of International Encyclopedia of Public Health. Oxford: Academic Press, 2008:255-67.
9. Ryall T. Health Minister Confirms New Medicines Spending, 30th July 2009. http://www.scoop.co.nz/stories/PA0907/S00395.htm (accessed 30 Sep. 2011).
10. Pharmaceutical Management Agency. Pharmaceutical Management Agency Annual Review. Wellington: PHARMAC, 2007.
11. Gregory W. PHARMAC: Getting The Best Bang for your Buck since 1993. Presentation at School of Pharmacy, University of Auckland, 2010.
12. Ministry of Health. Health and Independence Report. Wellington: Ministry of Health, 2003.
13. Babar Z. Scientific Inquiry and Pharmaceutical Policy: A preliminary Analysis from New Zealand. Canberra, Australia: National Medicines Symposium, 2008.
14. Pfizer New Zealand (UMR Research Limited). A Quantitative Study of Clinicians' Views on Pharmac. Auckland, New Zealand: UMR Research Ltd, 2005.
15. PHARMAC. Pharmac Stakeholder Research. Wellington: PHARMAC, 2007.
16. Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:c2441.
17. French S. A Thorn In Pharmac's Side. 2008. http://www.stuff.co.nz/ national/herceptin-debate/569569
18. Research Medicines Industry Institute. Access to Medicines Slow and Long. Wellington: Research Medicines Industry Institute, 2008.
19. Sundakov A. Funding High Cost Targeted Medicines: Improving the New Zealand approach: Australia Wyeth Pharmaceutical Position Paper. Wellington: Wyeth Pharmaceutical, 2008.
20. Auckland City Council. Auckland Council. 2011. http://www.aucklandcity. govt.nz/ (accessed 30 Sep. 2011).
21. Ministry of Health. District Health Boards. Wellington: Ministry of Health, 2010.
22. DHBNZ. Pharmacy Procedures Manual. Wellington, New Zealand: District Health Boards New Zealand, 2010. http://www.dhbnz.org.nz/Site/Pharmacy/ Procedures-Manual-published-version20100301.aspx (accessed 22 Mar. 2012).
23. PHARMAC. Pharmaceutical Management Agency of New Zealand. Wellington, New Zealand: Pharmaceutical Schedule, 2009.
24. Jatrana S, Crampton P, Norris P. Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health 2011;65:454-60.
25. MacKay P. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders? N Z Med J 2005;118:U1433.
26. Davies A, Metcalfe S, Moodie P, et al. PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J 2005;118:U1621.
27. Ministry of Health. Sector Services. Claims, Provider Payments & Entitlements: Special Authority. Wellington: Ministry of Health, 2008.
28. Pharmaceutical Management Agency. FAQ for GPs/Prescribers. Wellington: PHARMAC, 2010.
29. Moodie P, Metcalfe S, McCormack P. Response from PHARMAC: difficult choices. N Z Med J 2003;116:U361.
30. Pharmaceutical management agency. Diffuclt Choice. Wellington: PHARMAC, 2010.
31. BPACNZ. Accessing funded medicines in New Zealand. Best Practice Journal 2009:43-5.
32. New Zealand Dermatological Society Incorporated. Dermatologists Warning Over New Rules For Acne Drug-Media release December 20, 2008. New Zealand Dermatological Society Incorporated, 2008.
33. Ministry of Health British Columbia. What is Special Authority. British Columbia: Ministry of Health British Columbia. http://www.health.gov. bc.ca/pharmacare/sa/saindex.html (accessed 28 Sep. 2011).
34. Australian Government Department of Health and Ageing. Prescribing Medicines Information for PBS Prescribers. Canberra: Australian Government Department of Health and Ageing, 2011. http://www.medicareaustralia.gov. au/provider/pbs/prescriber/index.jsp
35. Tan NC, Tay IH, Ngoh A, et al. Factors influencing family physicians' drug prescribing behaviour in asthma management in primary care. Singapore Med J 2009;50:312.
36. Prescribing restrictions placed on UK GPs. Pharmacoeconomics & Outcomes News. 2011;627:2.
37. New Zealand Medicines and Medical Devices Safety Authority (Medsafe). Information for Health Professionals. Regulatory Issues. No Immediate Change to Generic. Wellington: Medsafe. http://www.medsafe.govt.nz/profs/riss/gensubleg (accessed 17 Jul. 2011).
38. European GenericMedicines Association. Generic Medicines, Basic Notions. Brussels: European Generic Medicines Association, 2002.
39. Babar Z U D, Stewart J, Reddy S, et al. An evaluation of consumers' knowledge, perceptions and attitudes regarding generic medicines in Auckland. Pharm World Sci 2010;32:440-8.
40. PHARMAC Consumer Advisory Committee. Minutes of the PHARMAC Consumer Advisory Committee (CAC) Meeting: Friday 13 July 2007. Wellington: PHARMAC, 2007.
41. Prosser H, Walley T. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc Sci Med 2005;60:1335-46. (Pubitemid 40038762)
42. Suggs LS, Raina P, Gafni A, et al. Family physician attitudes about prescribing using a drug formulary. BMC Fam Pract 2009;10:69.